6-mp

Z36-MP5 is an inhibitor targeting Mi-2β, exhibiting an IC50 of 0.082 μM. It is capable of diminishing Mi-2β ATPase activity and reactivating ISG transcription. Additionally, Z36-MP5 can enhance T-cell-mediated cytotoxicity [1].

6-MPR is a 2/6/8-modified purine nucleoside.

6-Mercaptopurine (6-MP) is an antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia.

6-Mercaptopurine hydrate (6-Mercaptopurine monohydrate) is a Nucleoside Metabolic Inhibitor. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia.

AS-136A is an orally active measles virus RNA-dependent RNA polymerase (RdRp) inhibitor with antiviral activity that inhibits measles virus and blocks viral RNA synthesis.

PU02 (6-[(1-Naphthalenylmethyl)thio]-9H-purine) is a potent and selective antagonist of 5-HT3 receptor.

Duazomycin (Duazomycin A) sodium acts as a glutamine antagonist. It significantly enhances the efficacy of 6-Mercaptopurine (6-MP) in treating experimental autoimmune encephalomyelitis (EAE) without increasing toxicity.

Azathioprine Sodium is the sodium salt form of azathioprine, a pro-drug of purine analogue with immunosuppressive activity. Azathioprine is converted in vivo to its active metabolite 6-mercaptopurine (6-MP), which substitutes for the normal nucleoside and mistakenly gets incorporated into DNA sequences. This leads to inhibition of DNA, RNA, and protein synthesis. As a result, cell proliferation may be inhibited, particularly in lymphocytes and leukocytes.

6-Mercaptopurine (Standard) is a reference standard for research and analysis in studies involving 6-Mercaptopurine. 6-Mercaptopurine (6-MP) is an antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia.

Amilo-5MER (5-MP) (TFA) is an orally active and selective inhibitor of serum amyloid A (SAA). It specifically inhibits the release of pro-inflammatory cytokines IL-6 and IL-1β in SAA-activated cells. Amilo-5MER (TFA) helps reduce chronic inflammation, alleviating symptoms associated with rheumatoid arthritis (RA), inflammatory bowel disease (IBD), and multiple sclerosis (MS). It holds potential for research into autoimmune and chronic inflammatory diseases.

Amilo-5MER (5-MP) is an orally active and selective inhibitor of serum amyloid A (SAA). It specifically suppresses the release of pro-inflammatory cytokines IL-6 and IL-1β in SAA-activated cells. Amilo-5MER reduces chronic inflammation and alleviates symptoms of diseases such as rheumatoid arthritis (RA), inflammatory bowel disease (IBD), and multiple sclerosis (MS). It holds potential for research in autoimmune and chronic inflammatory diseases.